← Leaderboards
Andre Francis Palmer
University Of Colorado Denver
$9,637,181
Attributed
$22,799,581
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,799,581 · 12
By mechanism
R01$22,399,831 · 11
R56$399,750 · 1
Top collaborators
- Pedro Cabrales18 shared
- Paul Werner Buehler16 shared
- David Charles Irwin12 shared
- Jeffrey John Chalmers5 shared
- Maciej Zborowski5 shared
- Francois Berthiaume4 shared
- Pravin Tp Kaumaya4 shared
- David W Wood4 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Paul Werner Buehler$4,588,385
- David Charles Irwin$10,493,842
Others in their field
Top investigators on “Hemoglobin”
- John M Lachin · George Washington University$134,552,372
- David M Nathan · Massachusetts Institute Of Technology$123,579,624
- Rose A Gubitosi-Klug · Case Western Reserve University$60,881,424
- Rohit Varma · University Of Southern California$56,341,998
- Anastassios G Pittas · Tufts Medical Center$38,762,359
- Lihong Wang · Texas A&M University System$33,028,686
Research focus
HemoglobinToxic EffectCellsBaseOxygenPhysiologicalProteinsPreventErythrocytesIn VivoEngineeringTissuesAnimalsHemodynamicsVasoconstrictionIn VitroBloodOrganHemeAnimal ModelHemorrhageHypertensionPolymersInnovation
Grant awards (48)
Engineering an Oxygen-Carrying Perfusate for Normothermic Machine Lung Perfusion$784,227
R01 · FY2025 · HL · contact PI
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$631,536
R01 · FY2025 · HL
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases$623,543
R01 · FY2025 · HL
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$629,898
R01 · FY2024 · HL
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$625,741
R01 · FY2024 · HL · contact PI
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases$611,072
R01 · FY2024 · HL
Engineering a novel biomaterial for oxygen transport applications$585,516
R01 · FY2024 · HL · contact PI
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$653,723
R01 · FY2023 · HL
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$646,411
R01 · FY2023 · HL · contact PI
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases$623,543
R01 · FY2023 · HL
Engineering a novel biomaterial for oxygen transport applications$613,884
R01 · FY2023 · HL · contact PI
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysis$701,968
R01 · FY2022 · HL
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$656,753
R01 · FY2022 · HL · contact PI
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseases$648,518
R01 · FY2022 · HL
Engineering a novel biomaterial for oxygen transport applications$636,624
R01 · FY2022 · HL · contact PI
Bioengineering a Dual Function Protein Construct to Detoxify Heme and Hemoglobin$703,990
R01 · FY2021 · HL · contact PI
Engineering a novel biomaterial for oxygen transport applications$664,429
R01 · FY2021 · HL · contact PI
PEGylated megahemoglobin for use as a red blood cell substitute$695,646
R01 · FY2020 · HL · contact PI
Fractionation of Aged RBCs Based on Hemoglobin Content$623,484
R01 · FY2020 · HL
PEGylated megahemoglobin for use as a red blood cell substitute$708,669
R01 · FY2019 · HL · contact PI
Fractionation of Aged RBCs Based on Hemoglobin Content$659,402
R01 · FY2019 · HL
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$371,545
R01 · FY2019 · HL · contact PI
Polymerized Hemoglobins for Facilitated Oxygen Transport in Hepatic Bioreactors$347,625
R01 · FY2019 · EB · contact PI
Fractionation of Aged RBCs Based on Hemoglobin Content$71,372
R01 · FY2019 · HL
PEGylated megahemoglobin for use as a red blood cell substitute$718,085
R01 · FY2018 · HL · contact PI
Fractionation of Aged RBCs Based on Hemoglobin Content$673,259
R01 · FY2018 · HL
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$457,459
R01 · FY2018 · HL · contact PI
Polymerized Hemoglobins for Facilitated Oxygen Transport in Hepatic Bioreactors$347,625
R01 · FY2018 · EB · contact PI
PEGylated megahemoglobin for use as a red blood cell substitute$752,718
R01 · FY2017 · HL · contact PI
Fractionation of Aged RBCs Based on Hemoglobin Content$714,715
R01 · FY2017 · HL
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$457,644
R01 · FY2017 · HL · contact PI
Polymerized Hemoglobins for Facilitated Oxygen Transport in Hepatic Bioreactors$347,625
R01 · FY2017 · EB · contact PI
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$31,923
R01 · FY2017 · HL · contact PI
Attenuating the Oxidative and Myocardial Side-Effects of Acellular Hemoglobin$388,699
R01 · FY2016 · HL · contact PI
Polymerized Hemoglobins for Facilitated Oxygen Transport in Hepatic Bioreactors$349,677
R01 · FY2016 · EB · contact PI
Attenuating the Oxidative and Myocardial Toxicity of Polymerized Hemoglobins$399,750
R56 · FY2014 · HL · contact PI
Mechanically Stable Blood Substitutes$348,233
R01 · FY2010 · HL · contact PI
Mechanically Stable Blood Substitutes$349,106
R01 · FY2009 · HL · contact PI
Mechanically Stable Blood Substitutes$265,416
R01 · FY2009 · HL · contact PI
Mechanically Stable Blood Substitutes$18,336
R01 · FY2009 · HL · contact PI
Enhanced O2 Delivery to C3A Hepatocytes$1,500
R01 · FY2009 · DK · contact PI
Mechanically Stable Blood Substitutes$349,930
R01 · FY2008 · HL · contact PI
Enhanced O2 Delivery to C3A Hepatocytes$189,840
R01 · FY2008 · DK · contact PI
Mechanically Stable Blood Substitutes$350,707
R01 · FY2007 · HL · contact PI
Enhanced O2 Delivery to C3A Hepatocytes$193,715
R01 · FY2007 · DK · contact PI
Mechanically Stable Blood Substitutes$332,340
R01 · FY2006 · HL · contact PI
Enhanced O2 Delivery to C3A Hepatocytes$199,500
R01 · FY2006 · DK · contact PI
Mechanically Stable Blood Substitutes$42,660
R01 · FY2006 · HL · contact PI